A Phase 3 Clinical Study of KHK 4827

NCT02052609 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

155

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis Vulgaris
Psoriatic Arthritis
Pustular; Psoriasis, Palmaris Et Plantaris
Psoriatic Erythroderma

Interventions

DRUG: KHK4827 140mg SC
DRUG: KHK4827 210mg SC

Sponsor

Kyowa Kirin Co., Ltd.